ABL1
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase; also c-ABL, ABL, p150 and JTK7) is a non-receptor tyrosine kinase that links extracellular stimuli to cell growth, survival, cytoskeleton remodelling and the DNA damage response. It is best known as a proto-oncogene fused to BCR in leukaemia. Browse Assay Genie's current range of ABL1 research reagents below, or read on for the biology behind the target.
ABL1 is a non-receptor tyrosine-protein kinase that acts in many processes linked to cell growth and survival, including cytoskeleton remodelling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. It coordinates actin remodelling by phosphorylating proteins that control cytoskeleton dynamics, such as WASF3, cortactin (CTTN), ENAH and paxillin (PXN). Phosphorylation of WASF3 is critical for lamellipodia formation and cell migration. ABL1 also phosphorylates adhesion regulators including BCAR1, CRK, CRKL, DOK1 and NEDD9, and receptor-linked targets such as EGFR, MUSK and PDGFRB.
The ABL1 protein shuttles between compartments. In the nucleus it has DNA-binding activity and phosphorylates DNA repair proteins including RAD51, RAD52 and WRN; when damage is too severe to repair, it activates the proapoptotic pathway through TP73 and CASP9. It targets to mitochondria under oxidative stress, where it mediates mitochondrial dysfunction and cell death. ABL1 also regulates its own activity through autocatalysis and phosphorylation of its inhibitor ABI1, and it positively regulates chemokine-mediated T-cell migration and, via TBX21, T-cell differentiation. Several microbial proteins, including Vaccinia A36R and H. pylori CagA, are ABL1 substrates that pathogens exploit to reorganise the host actin cytoskeleton.
ABL1 belongs to the Tyr protein kinase family, ABL subfamily, and contains SH2 and SH3 domains. The SH3 domain negatively regulates activity; deleting the region encoding it produces an oncogene. The protein is ubiquitously expressed, and its DNA-binding activity is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. The ABL1 gene is fused to many partners in leukaemias, most notably BCR in the t(9;22) translocation. Alternative splicing gives two transcript variants with different first exons. Earlier names include v-abl Abelson murine leukaemia viral oncogene homolog 1 and c-abl oncogene 1.
ABL1 is fused to partner genes in various leukaemias, most notably BCR, making it central to studies of translocation-driven kinase activation.
Nuclear ABL1 phosphorylates DNA repair proteins and activates TP73 and CASP9 when damage is too severe to repair.
ABL1 phosphorylates WASF3, cortactin and paxillin to control actin remodelling, lamellipodia formation, adhesion and motility.
Microbial proteins such as Vaccinia A36R and H. pylori CagA are ABL1 substrates that pathogens use to reorganise host actin.
ABL1 is a non-receptor tyrosine kinase that regulates cytoskeleton remodelling, cell adhesion and motility, receptor endocytosis, autophagy, DNA damage response and apoptosis. It phosphorylates substrates such as WASF3, CRK, EGFR, TP73 and CASP9, and regulates itself through autocatalytic activity and phosphorylation of ABI1.
ABL1 is also known as c-ABL, ABL, p150 and JTK7. Earlier names include v-abl Abelson murine leukaemia viral oncogene homolog 1 and c-abl oncogene 1. Alternative splicing of the gene gives two transcript variants that differ in their first exons.
The ABL1 gene is fused to various partners in leukaemias, most notably BCR in the t(9;22) translocation. Loss of SH3-mediated negative regulation also makes it oncogenic. The mouse ortholog is Abl1; check the datasheet of any product for its validated reactivity.
Other ABL-family and ABL-related targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P00519; product specifications from Assay Genie datasheets.